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Pachyonychia congenita (PC) is an autosomal domi-
nant genodermatosis caused by heterozygous
mutations in any one of the genes encoding the
differentiation-specific keratins K6a, K6b, K16, or K17.
The main clinical features of the condition include
painful and highly debilitating plantar keratoderma,
hypertrophic nail dystrophy, oral leukokeratosis, and a
variety of epidermal cysts. Although the condition
has previously been subdivided into PC-1 and PC-2
subtypes, the phenotypic characterization of 1,000
mutation-verified PC patients enrolled in the Interna-
tional PC Research Registry, coordinated by the
patient advocacy group PC Project, shows that there
is considerable overlap between these subtypes.
Thus, a new genotypic nomenclature is proposed, in
which PC-6a represents a patient carrying a mutation
in the K6a gene, etc. Although a rare disorder, PC
represents a good model for therapy development,
and international efforts are ongoing to develop and
deliver siRNA, gene, correction, small molecule, and
other strategies to treat this painful, disabling
skin condition. The special relationship between PC
Project and the PC research community has greatly
accelerated the development pathway from gene
identification to clinical trials in only a few years and
represents a paradigm of hope for other orphan
diseases.
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INTRODUCTION
Pachyonychia congenita (PC) is an uncommon autosomal
dominant disorder of keratinization caused by mutations in
any one of a number of keratin genes that are expressed
in differentiated epithelial tissues. The condition was first
described in the early twentieth century (Jadassohn and
Lewandowski, 1906; Jackson and Lawler, 1951) but it was
not until the early 1990s, with the emergence of molecular
genetics technology, that the causative gene in a large
Scottish PC family was mapped to one of the keratin gene
clusters (Munro et al., 1994). Shortly thereafter, the causative
mutations were identified in several PC patients in the KRT6A,
KRT6B, KRT16, and KRT17 genes, encoding the keratin
proteins K6a, K6b, K16, and K17, respectively (Bowden
et al., 1995; McLean et al., 1995; Smith et al., 1998).
Keratins are the intermediate filament proteins specifically
expressed by epithelial cells, in which they form a dense
cytoplasmic network (Irvine and McLean, 1999; Omary et al.,
2004). The primary function of the keratin cytoskeleton is to
impart mechanical strength and resilience to epithelial cells
and tissues. Disruption of this cytoskeletal system due to a
genetic mutation in a keratin gene leads to extreme fragility of
the epithelial cells and tissues in which the mutated keratin is
expressed. Similar to several other keratin disorders, the
vast majority of causative mutations in the PC-related keratins
are heterozygous missense mutations or small insertion/
deletion mutations that disrupt cytoskeletal function via
dominant-negative interference and lead to epithelial cell
fragility (McLean et al., 2005). In PC, this is manifest as
cytolysis and hyperkeratosis in the subset of differentiated
epithelial tissues in which K6a, K6b, K16, and K17 are
predominantly expressed (Lane, 1993), specifically the
palmoplantar epidermis, nail bed, mucosae, and the pilose-
baceous unit. Thus, the cardinal phenotypic features
of PC are palmoplantar (predominantly plantar) keratoderma;
hypertrophic nail dystrophy; oral leukokeratosis; and a
variety of cysts arising from hyperkeratosis of pilosebaceous
apparatus (Figure 1).
A MOLECULAR CLASSIFICATION FOR PC SUBTYPES
In 2003, a patient advocacy group—Pachyonychia Congenita
Project—was established to support those affected by PC
and to both encourage and fund research into a cure for the
condition (www.pachyonychia.org). To achieve this goal,
the International PC Consortium (IPCC) was founded in early
2004. This is a group of clinicians and scientists actively
researching the causes of PC and importantly, the development
of new treatments for PC. The IPCC has met annually since
2004 and its membership is listed at www.pachyonychia.org.
An important part of the ongoing PC research program is
the International PC Research Registry (IPCRR), in which
detailed phenotypic data are collected from patients and
linked to genetic data. At the time of writing, close to 1000
PC patients have been identified by the PC Project. This has
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led to the largest collection of linked clinical and genetic
information yet assembled for a rare keratin disorder.
Historically, PC has been split into two subtypes (PC-1, or
Jadassohn–Lewandowski subtype; and PC-2, or the Jackson–-
Lawler subtype) on the basis of subtle differences in
phenotype, primarily the presence or absence of pilosebac-
eous cysts (Jadassohn and Lewandowski, 1906; Jackson
and Lawler, 1951). At present, with analysis of hundreds of
patients in the IPCRR, limitations in the older classification,
which was based on only a handful of non-genotyped cases,
have become clear. In particular, many PC patients,
regardless of genotype, have some form of epidermal cysts
(see Wilson et al., 2011). Therefore, on the basis of the more
comprehensive IPCRR data, a more rational and useful
classification based on the mutated gene was proposed at
the 2010 IPCC Symposium and has been adopted throughout
the research papers in this issue of the JID. The new
classification is PC-6a, PC-6b, PC-16, and PC-17, for a patient
with a mutation in the gene encoding K6a and others proteins
(the complete data set underlying this new nomenclature
will be published elsewhere; Eliason et al., unpublished data).
In cases in whom PC is suspected but no mutation has been
found (or not looked for), the term PC-U (for unknown) will
be used.
The predominant symptom in PC is plantar pain
Although hypertrophic nail dystrophy is the phenotypic
feature that gave rise to the name of the condition, the most
problematic symptom reported by PC patients is focal plantar
keratoderma that is associated with severe pain. The plantar
pain in PC is often highly debilitating and has considerable
negative effect on quality of life. The reason for the pain is not
fully understood but is thought to be related to blister
formation deep underneath the thick callus that develops
over the pressure points of the plantar surface (see Figure 1a).
Plantar blistering, together with accompanying pain, is a
common feature of PC that is under-reported in the literature
(Eliason et al., unpublished data).
Nail dystrophy (Figure 1b), which can occur from a very
early age, is variable in severity and in many cases not all 20
nails are affected. Toenails are more commonly affected than
fingernails, which could be because of greater trauma exerted
from shoes. Another feature of PC is oral leukokeratosis
(Figure 1c). This is often one of the first signs of PC in babies
and may lead to difficulty in feeding and is often mistaken for
candidiasis in infants. Follicular keratoses are present in
many cases of PC. Some individuals also develop cysts in the
form of steatocysts (steatocystomas) and/or pilosebaceous
cysts (Figure 1d). This feature is particularly associated with
patients with a K17 mutation (see Wilson et al., this issue), in
whom sometimes it is necessary to remove cysts surgically.
The severity of the clinical features of PC can vary quite
widely both among and within families. This may partly be
because of individual lifestyle and care of PC and could also
be because of the specific type of mutation, as well as other




Figure 1. The cardinal clinical characteristics of PC. (a) Focal plantar keratoderma, with recurrent blistering underneath the callus, is the main source of
pain and disability in PC. This individual is a heterozygous carrier of the K16 mutation L132P (p.Leu132Pro). (b) Typical hypertrophic nail dystrophy that
gives the condition its name. The nail changes are quite variable in PC families, even among people with the same mutation. In some cases, the fingernails
are spared. This patient carries the K17 mutation L95Q (p.Leu95Gln). (c) Oral leukokeratosis is a common feature of PC, readily seen here as lingual
leukokeratosis in a patient carrying the most common PC mutation, N172del (p.Asn172del) in K6a. (d) PC patients suffer from a variety of epidermal cysts,
including follicular keratoses and pilosebaceous cysts that can resemble steatocysts or epidermoid cysts. The latter are more abundant in patients with
K17 mutations, as shown here in a patient carrying the K17 mutation N92D (p.Asn92Asp). PC, pachyonychia congenita.
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Rapid therapy development in PC
Although it is a rare condition, PC is at the forefront of
genetic therapy development in the dermatology field.
In particular, the dominant-negative genetic mechanism in
PC contributes to therapeutic strategies based on RNA
interference (RNAi), especially in the form of short interfering
RNA (siRNA). It has been demonstrated that mutant keratin
alleles differing from wild type by a single-nucleotide point
mutation can be potently and specifically silenced
by carefully designed siRNA (Hickerson et al., 2008). This
mutation-specific siRNA therapy approach has been pro-
gressed into the recently reported small-scale human clinical
trial, in which efficacy was demonstrated (Leachman et al.,
2010). This was the first time that siRNA had been used to
treat a human skin disorder. The keratins involved in PC also
show considerable functional redundancy, in particular when
K6 is involved. Humans have three copies of a nearly
identical KRT6 gene, encoding the K6a, K6b, and K6c
proteins. Mouse knockout experiments strongly suggest that
loss of one of these keratins may be tolerated (Wong et al.,
2000; Wojcik et al., 2001) and therefore an alternative
therapeutic approach would be to completely silence the
defective keratin, regardless of mutation. To this end, highly
potent gene-specific siRNA has been developed for PC (Smith
et al., 2008). The major technical hurdle yet to overcome in
both these therapeutic approaches is the development of a
safe, effective, and patient-friendly method for routine
delivery of siRNA into the epidermis. This is currently a
major goal of the IPCC research groups, in addition to
development of alternative therapies that include gene
correction methodology, small molecule therapy, and other
strategies (Kaspar et al., this issue).
CONCLUSION
Over the past 7 years, the PC research field represents a great
example of how a small group of highly motivated patients and
their families, together with a group of interested clinicians and
scientists, can rapidly progress research from knowing only the
identity of a gene defect to having new therapies that show
efficacy in cells, in animal models, and in patients. Hopefully,
this sustained, highly focused effort will shortly lead to a
successful and widely applicable treatment for PC and the
lessons learned along the way can be translated to other genetic
skin disorders.
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